https://www.globenewswire.com/news-release/2021/12/21/2355961/0/en/PharmaTher-Provides-Update-on-Product-Pipeline-and-Expected-Milestones-for-2022.html

Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022 include initiating Phase 3 clinical study for ketamine to treat Parkinson’s disease (KETLID); completing Phase 2 clinical study for ketamine to treat ALS (KETALS); completing observational study with ketamine and betaine for depression and pain…

Source